49th ASH^® Annual Meeting and Exposition
December 8-11, 2007

Georgia World Congress Center
Atlanta, Georgia

Abstracts | Important Dates | Schedule At-a-Glance | Special Lectures | Special Interest Sessions | Education Program | Education Spotlight Sessions | Scientific Program | Meet-the-Expert Sessions | Oral and Poster Sessions | Trainee Activities and Services | ASH Business Meeting | Social Events | Exposition | Registration | Hotel Accommodations | CME Credits | Attendee Services | Travel | Atlanta | ASH Publications and Meeting Materials | Meeting Rules and Regulations | Speaker Preparation and Conflict of Interest | Friday Satellite Symposia

Friday Satellite Symposia
Friday, December 7

ASH would like to thank the participating sponsors of this year’s Friday Satellite Symposia. ASH views the Friday Satellite Symposia as a strong example of a healthy partnership between the Society and the corporate community, research-based companies, nonprofit organizations, and others who play an important role in providing meeting attendees with quality educational programs.

The following are confirmed Friday Satellite Symposia as of May 2007. These symposia are not part of the official 2007 ASH Annual Meeting, and an ASH badge is not needed to attend them. Each symposium is planned solely by the sponsoring organization, which will send detailed information and invitations prior to the meeting.

7:00 a.m. - 11:00 a.m.

Chronic Lymphocytic Leukemia as a Model of Translational Research
University of Rochester Continuing Professional Education and supported by the Leukemia and Lymphoma Society.

7:00 a.m. - 11:00 a.m. • Omni Hotel at CNN Center – International Ballroom E-F

Speakers:

• George Calin, MD, PhD, Ohio State Comprehensive Cancer Center, Columbus, OH
• Thomas J. Kipps, MD, PhD, University of California – San Diego, La Jolla, CA
• David G. Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA
• Michael J. Keating, MBBS, The University of Texas M.D. Anderson Cancer Center, Houston, TX
• John Gribben, MD, DSc, Institute of Cancer, Center for Medical Oncology, Barts and the London School of Medicine, London, United Kingdom

This symposium encompasses new approaches in the diagnosis, treatment, and prognosis of chronic lymphocytic leukemia. This includes advances in microRNA in its onset and progression, prognosis markers, the opportunities for gene therapy, allogeneic stem cell transplantation and other immune therapies, and current and future drug therapy.

For more information, contact Allyson O’Connor, Leukemia and Lymphoma Society.

Phone: 914-821-8838
Fax: 914-821-3638
E-mail: allyson.oconnor@lls.org

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. George Calin indicated no conflicts of interest.
• Dr. Thomas J. Kipps indicated no conflicts of interest.
• Dr. David G. Maloney indicated no conflicts of interest.
• Dr. Michael J. Keating indicated no conflicts of interest.
• Dr. John Gribben: consultant for Roche and Biogen Idec; speakers bureau for Roche, Genentech, and Bayer.

The Future of Clinical Research in HCT:
Reports from the 2007 State of the Science Symposium
This program is sponsored by the Medical College of Wisconsin and supported by the National Marrow Donor Program.

7:00 a.m. - 11:00 a.m. • Georgia World Congress Center - Sidney Marcus Auditorium

Speakers:

• James L.M. Ferrara, MD, University of Michigan, Ann Arbor, MI
• Mary M. Horowitz, MD, MS, Medical College of Wisconsin, Milwaukee, WI
• Joseph H. Antin, MD, Dana-Farber Cancer Institute, Boston, MA
• Daniel Weisdorf, MD, University of Minnesota, Minneapolis, MN
• Dennis L. Confer, MD, National Marrow Donor Program, Minneapolis, MN

This symposium will present the conclusions from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 2007 State of the Science Symposium. This conference brought together leaders in the field who intensively evaluated scientific advances and challenges in each of 12 areas of focus. This symposium will present, for the first time, their recommendations for translational and clinical research studies most likely to advance the field.

For more information, contact Renee Ryan, National Marrow Donor Program.

Phone: 612-884-8430
Fax: 612-627-5877
E-mail: rryan@nmdp.org

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. James L.M. Ferrara: speakers bureau for Therakos.
• Dr. Mary M. Horowitz indicated no conflicts of interest.
• Dr. Joseph H. Antin indicated no conflicts of interest.
• Dr. Daniel Weisdorf: research support from Amgen, Roche, Ligand, SuperGen, Cephalon, and Therakos.
• Dr. Dennis L. Confer indicated no conflicts of interest.

12:30 p.m. - 4:30 p.m.

Thrombocytopenia Treatment Exposed: Challenging Cases Brought to Life
This program is sponsored by the Curatio CME Institute,
LLC, and supported by Amgen, Inc.

12:30 p.m. – 4:30 p.m. • Omni Hotel at CNN Center – Grand Ballroom D2-E

Speakers:

• James N. George, MD, University of Oklahoma Health Sciences Center, Oklahoma City, OK
• David J. Kuter, DPhil, MD, Massachusetts General Hospital, Boston, MA
• Victor S. Blanchette, MD, FRCP, University of Toronto, Toronto, Canada
• Taroh Kinoshita, PhD, Osaka University, Osaka, Japan
• Eva Hellström-Lindberg, MD, PhD, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden

This CME symposium will address the many questions that clinical experts are asked throughout the year when consulted on difficult clinical thrombocytopenia cases. This format will allow the learner to become engaged through the use of an audience response system (ARS).

For more information, contact Kristen Petro, Curatio CME Institute, LLC.

Phone: 610-363-1619, ext. 115
Fax: 610-363-7410
E-mail: kristen.petro@curatiocme.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. James N. George: research support from and consultant for Amgen.
• Dr. David J. Kuter: research support from Amgen.
• Dr. Victor S. Blanchette: consultant for Baxter BioScience, Bayer, and ZLB Behring; speaker for Baxter BioScience, Bayer, and Wyeth.
• Dr. Eva Hellström-Lindberg: speaker for Celgene and Pharmion; research support from Pharmion; consultant for Amgen.

Great Debates in CLL: Facing Today's Controversies and Tomorrow's Challenges
This program is sponsored by Imedex Accreditation Services, Inc., and supported by Bayer HealthCare Pharmaceuticals.

12:30 p.m. - 4:30 p.m. • Georgia World Congress Center – Sidney Marcus Auditorium

Speakers:

• Susan O’Brien, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX
• Alessandra Ferrajoli, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX
• Mark A. Weiss, MD, Memorial Sloan-Kettering Cancer Center, New York, NY
• Stephan Stilgenbauer, MD, University of Ulm, Ulm, Germany
• Martin J.S. Dyer, MA, DPhil, FRCP, Leicester University, Leicester, United Kingdom
• John C. Byrd, MD, The Ohio State University, Columbus, OH

The overall purpose of this activity is to provide an interactive, highly educational format that will include friendly debates, didactic presentations, and case-based discussions. This educational activity is designed to provide participants with the latest information in the field of hematology and a deeper understanding of the ongoing clinical challenges and areas of controversy.

For more information, contact Lori Scholle, Imedex and the American School of Oncology.

Phone: 770-751-7332
Fax: 770-751-7334
E-mail: lori.scholle@asoncology.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Susan O’Brien: research support from Berlex Laboratories, Biogen Idec, and Genentech.
• Dr. Alessandra Ferrajoli: research support from Berlex Laboratories and Celgene.
• Dr. Mark A. Weiss: research support from Berlex Laboratories, Genentech, and Hospira.
• Dr. Stephan Stilgenbauer: research support, advisory board participation, and honorarium from Amgen, Bayer, Ribosepharm, Roche, Santaris Pharma, and Schering.
• Dr. Martin J.S. Dyer: honoraria from Berlex Laboratories and Schering-Plough.
• Dr. John C. Byrd: research support and clinical trial work for Biogen Idec, Geron, Novartis, and Pharmion.

Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibition:
Clinical Considerations and Interactive Case Studies
This program is sponsored by SciMed, LLC, and supported by Bristol-Myers Squibb Company.

12:30 p.m. - 4:30 p.m. • Georgia World Congress Center – Georgia Ballroom

Speakers:

• Jorge Cortes, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX
• Jane F. Apperley, MB ChB, Hammersmith Hospital, Imperial College School of Medicine, London, United Kingdom
• Moshe Talpaz, MD, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
• Michael J. Mauro, MD, Oregon Health and Science University, Portland, OR
• Jerald P. Radich, MD, Fred Hutchinson Cancer Research Center, Seattle, WA
• Michael W.N. Deininger, MD, PhD, Oregon Health and Science University, Portland, OR
• Neil P. Shah, MD, PhD, University of California – San Francisco, San Francisco, CA

This symposium will identify the underlying genetic aberrations responsible for CML progression and explain the rationale for utilizing targeted tyrosine kinase inhibitors, analyze and extrapolate the results of hematologic, cytogenetic, and molecular methodologies to guide management strategies, and differentiate adverse events of first and second generation TKIs for CML and Ph+ ALL to better identify optimal management approaches. Symposium speakers will also compare and contrast new treatment guidelines with existing long-term management strategies for CML and Ph+ ALL patients with early signs of disease progression.

For more information, contact Pablo Luzuriaga, SciMed, LLC.

Phone: 646-823-2651
Fax: 646-873-5569
E-mail: pluzuriaga@scimedny.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Jorge Cortes: research support from Bristol-Myers Squibb, Novartis, Schering-Plough, Wyeth, Tibotec, Breakthrough Therapeutics, the Vaccine Company, and ChemGenex.
• Dr. Jane F. Apperley: advisory board member for Bristol-Myers Squibb and Novartis.
• Dr. Moshe Talpaz: research support, consultant, and speakers bureau for Bristol-Myers Squibb and Novartis.
• Dr. Michael J. Mauro: research support from Bristol-Myers Squibb; speakers bureau for Bristol-Myers Squibb and Novartis.
• Dr. Jerald P. Radich: research support from and consultant for Bristol-Myers Squibb and Novartis.
• Dr. Michael W.N. Deininger: research support from Ambit, SGX Pharmaceuticals, and Calistoga Pharmaceuticals; consultant for Bristol-Myers Squibb and Novartis.
• Dr. Neil P. Shah: research support from Bristol-Myers Squibb.

Elderly AML: A Problem in Search of a Solution
This program is sponsored by Educational Concepts Group, Inc., and supported by Genzyme Corporation.

12:30 p.m. - 4:30 p.m. • Omni Hotel at CNN Center – International Ballroom E-F

Speakers:

• Hagop M. Kantarjian, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX
• Frederick R. Appelbaum, MD, Fred Hutchinson Cancer Research Center, Seattle, WA
• Joseph Menzin, PhD, Boston Health Economics, Inc., Waltham, MA
• Charles A. Schiffer, MD, Barbara Ann Karmanos Cancer Institute, Detroit, MI
• Lazzaro Repetto, MD, PhD, Instituto Nazionale di Riposo e Cura per Anziani, Rome, Italy
• Alan K. Burnett, MD, FRCP, Cardiff University School of Medicine, Cardiff, United Kingdom
• Lewis R. Silverman, MD, Mount Sinai School of Medicine, New York, NY
• Elias J. Anaissie, MD, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR

This live, independent educational program will provide hematologists and other allied health-care professionals who treat elderly patients with AML with pertinent information about management issues and treatment.

For more information, contact Tina Stacy, Educational Concepts Group, Inc.

Phone: 770-933-1684
Fax: 770-953-1692
E-mail: tstacy@educationalconcepts.net

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Hagop M. Kantarjian: research support from Novartis, Bristol-Myers Squibb, and MGI Pharma.
• Dr. Frederick R. Appelbaum indicated no conflicts of interest.
• Dr. Joseph Menzin indicated no conflicts of interest.
• Dr. Charles A. Schiffer indicated no conflicts of interest.
• Dr. Lazzaro Repetto indicated no conflicts of interest.
• Dr. Alan K. Burnett: research support from Bioenvision.
• Dr. Lewis R. Silverman: research support from Celgene and Pharmion.
• Dr. Elias J. Anaissie: research support from Pfizer, Astellas, Amgen, Ortho Biotech, CuraGen; consultant for Pfizer, Astellas, Amgen, Gilead Sciences; speakers bureau for Pfizer, Merck, Schering-Plough, Gilead Sciences, Astellas, and Amgen.

Hypereosinophilic Syndromes (HES) – An Interactive Discussion on this Sometimes Difficult Group of Disorders: Causes, Differential Diagnosis, and Potential Treatments
This program is sponsored by the University of Kentucky and supported by GlaxoSmithKline.

12:30 p.m. - 4:30 p.m. • Georgia World Congress Center – B211-B212

Speakers:

• Gerald Gleich, MD, University of Utah, Salt Lake City, UT
• Adrian Newland, FRCP, The Royal London Hospital, London, United Kingdom
• Lawrence Schwartz, MD, Virginia Commonwealth University, Richmond, VA
• Michael Wechsler, MD, Harvard Medical School, Boston, MA
• Peter Weller, MD, Harvard Medical School, Boston, MA
• Florence Roufosse, MD, Erasme Hospital, Brussels, Belgium

This symposium will utilize didactic presentation combined with audience participation, encouraged throughout the program through the use of an interactive questioning (ARS) system. Outcomes measurements will be started during the invitation process, where short pre-survey knowledgeassessment questions will be asked of invitees in conjunction with their symposium pre-registration. Results of these questions will be analyzed and presented at the program.

For more information, contact Barbara Lovit, Continuing Edge, a division of Global Edge, Inc.

Phone: 212-792-6628
Fax: 212-792-6658
E-mail: blovit@globaledge-us.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Gerald Gleich: speakers bureau for Novartis and Genentech; consultant for GlaxoSmithKline.
• Dr. Adrian Newland: speakers bureau for GlaxoSmithKline, Gilead, and Amgen; research support from GlaxoSmithKline, Gilead, Amgen, and Baxter; consultant for Schering-Plough, GlaxoSmithKline, and PanGenetics.
• Dr. Michael Wechsler: speakers bureau for Merck, Genentech, and Novartis; research support from GlaxoSmithKline; consultant for Merck, Genentech, Novartis, and Schering-Plough.
• Dr. Peter Weller: consultant for GlaxoSmithKline.
• Dr. Florence Roufosse: research grant from the Belgian National Fund for Scientific Research; consultant for GlaxoSmithKline.

Changing Paradigm in Anticoagulation! Will Heparins and Oral Anticoagulants Survive?
This program is sponsored by Loyola University Medical Center and supported by Loyola University – Hemostasis Research Laboratories.

12:30 p.m. - 4:30 p.m. • Georgia World Congress Center – B312-B314

Speakers:

• Debra Hoppensteadt, PhD, Loyola University Medical Center, Maywood, IL
• Ajay Kakkar, MD, PhD, London University, London, United Kingdom
• Arthur Sasahara, MD, Harvard University, Boston, MA
• Leo R. Zacharski, MD, Dartmouth Medical School, White River Junction, VT
• Russell Hull, MD, University of Calgary, Calgary, Canada
• Eugene Frenkel, MD, University of Texas, Dallas, TX
• Jeanine Walenga, PhD, Loyola University Medical Center, Maywood, IL
• Jawed Fareed, PhD, Loyola University Medical Center, Maywood, IL
• Craig M. Kessler, MD, Georgetown University Medical Center, Washington, DC
• Roger Bick, MD, PhD, University of Texas, Houston, TX

This symposium will provide an objective update on the use of conventional and newer agents used in the management of thrombosis. Such drugs as pentasaccharide, antithrombin, and anti-Xa will be discussed.

For more information, contact Debra Hoppensteadt, Loyola University Medical Center.

Phone: 708-216-4625
Fax: 708-216-6660
E-mail: dhoppen@lumc.edu

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Debra Hoppensteadt: research support from sanofi aventis U.S. and Mitsubishi Pharma Corporation.
• Dr. Ajay Kakkar: research support from and consultant for sanofi aventis U.S..
• Dr. Arthur Sasahara indicated no conflicts of interest.
• Dr. Leo R. Zacharski: consultant for AstraZeneca, Bayer, Pfizer, Pharmion, and sanofi aventis U.S.; speakers bureau for sanofi aventis U.S..
• Dr. Russell Hull: consultant for Leo Pharma and Pfizer; advisory board member for sanofi aventis U.S., Bayer, Wyeth, and GlaxoSmithKline.
• Dr. Eugene Frenkel indicated no conflicts of interest.
• Dr. Jeanine Walenga indicated no conflicts of interest.
• Dr. Jawed Fareed: research support from Mitsubishi Pharma Corporation.
• Dr. Craig M. Kessler: consultant for sanofi aventis U.S., Pfizer, and GlaxoSmithKline; research support from and speakers bureau for sanofi aventis U.S..
• Dr. Roger Bick indicated no conflicts of interest.

The Hematology Circle – Rebalancing Molecular Profiles in Hematologic Malignancies: New Technologies for Targeting Silenced and Overexpressed Genes
This program is sponsored by i3 CME and supported by Merck and Co., Inc.

12:30 p.m. - 4:30 p.m. • Georgia World Congress Center – C306-C308

Speakers:

• Steven T. Rosen, MD, Feinberg School of Medicine, Northwestern University Medical School, Chicago, IL
• David A. Rizzieri, MD, Duke Comprehensive Cancer Center, Durham, NC
• Richard M. Stone, MD, Dana-Farber Cancer Institute, Boston, MA
• Guillermo Garcia-Manero, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX

The purpose of this educational activity is to revisit the cellular processes integral to the pathogenesis of leukemias and lymphomas in the context of new chemotherapeutics, biologics, and management strategies.

For more information, contact Nora Flynn, i3 CME.

Phone: 973-647-6924
Fax: 973-241-9462
E-mail: nora.flynn@i3cme.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Steven T. Rosen: research support from Celgene, Bayer HealthCare Pharmaceuticals, and Merck; consultant for Celgene and Bayer HealthCare Pharmaceuticals; advisory board for Celgene, Bayer HealthCare Pharmaceuticals, Allos Therapeutics, Abbott Laboratories, and Therakos; speakers bureau for Celgene, Bayer HealthCare Pharmaceuticals, and Merck.
• Dr. David A. Rizzieri: advisory board and speakers bureau for Bayer HealthCare Pharmaceuticals, Novartis, Biogen Idec, GlaxoSmithKline, and Millennium Pharmaceuticals.
• Dr. Richard M. Stone: research support from Novartis and Bristol-Myers Squibb; consultant for Johnson and Johnson, Hana Biosciences, and Genzyme; advisory board for Amgen, MGI Pharma, PhRMA, and Merck; speakers bureau for Bristol-Myers Squibb, Pharmion, and Celgene.
• Dr. Guillermo Garcia-Manero: research support from the National Institutes of Health, the Leukemia and Lymphoma Society of America, Pharmion, MGI Pharma, and Merck; consultant for Pharmion, MGI Pharma, and Merck; speakers bureau for Pharmion and MGI Pharma.

Promising Directions in Myeloma and Lymphoproliferative Disorders: Approaching Resistance, Retreatment, and Maintenance Through Novel Clinical Pathways
This program is sponsored by the Postgraduate Institute of Medicine and supported by Millennium Pharmaceuticals and Ortho Biotech.

12:30 p.m. - 4:30 p.m. • Georgia World Congress Center – B302-B305

Speakers:

• Asher A. Chanan-Khan, MD, Roswell Park Cancer Institute, Buffalo, NY
• Michele Ghielmini, MD, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
• Andre Goy, MD, Hackensack University Medical Center, Hackensack, NJ
• Sagar Lonial, MD, Emory University School of Medicine, Atlanta, GA
• Peter McLaughlin, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX
• Michael Pfreundschuh, MD, PhD, University of Saarland, Homburg, Germany
• Steven P. Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA

Given that the field of multiple myeloma therapeutics is rapidly evolving, there is a pressing need for educational activities that keep clinicians abreast of any and all advances in multiple myeloma treatment activities. This symposium will provide updates on investigational and currently approved therapies for treating multiple myeloma in the front-line, relapsed/refractory, and non-transplant settings.

For more information, contact Eleanor Gallelli, Clinical Care Options, LLC.

Phone: 703-674-3524
Fax: 703-391-6874
E-mail: egallelli@clinicaloptions.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Asher A. Chanan-Khan: consultant for Millennium Pharmaceuticals, Celgene, and Kosan Biosciences; research support from Celgene.
• Dr. Michele Ghielmini: consultant for Roche.
• Dr. Andre Goy: consultant for Millennium Pharmaceuticals and Genentech.
• Dr. Sagar Lonial: consultant for Millennium Pharmaceuticals and Celgene.
• Dr. Peter McLaughlin: consultant for Genentech.
• Dr. Michael Pfreundschuh: consultant for Roche, Genentech, and Eli Lilly.
• Dr. Steven P. Treon: consultant for Genentech, Biogen Idec, Celgene, and Millennium Pharmaceuticals.

Changing the Characterization of MDS: Diagnosis to Therapy
This program is sponsored by Educational Review Systems and supported by the Myelodysplastic Syndromes Foundation, Inc.

12:30 p.m. - 4:30 p.m. • Georgia World Congress Center – Thomas Murphy Ballroom 1-2

Speakers:

• John M. Bennett, MD, University of Rochester, Rochester, NY
• Ulrich Germing, MD, Heinrich-Heine University of Dusseldorf, Dusseldorf, Germany
• Denise Wells, MD, Hematologics, Inc., Seattle, WA
• Allen Yang, MD, PhD, University of Southern California, Los Angeles, CA
• Jaroslaw Maciejewski, MD, Cleveland Clinic Foundation, Cleveland, OH
• Stephen Nimer, MD, Memorial Sloan-Kettering Cancer Center, New York, NY

This symposium will focus on the ever-unfolding morphologic and response-assessment criteria, the impact of karyotypic abnormalities and the acquisition of new abnormal karyotypes as they relate to disease progression, current molecular genetic research on therapeutic targeting of the epigenome, the need for targeted therapies and combination therapies, and the evaluation of therapeutic interventions based upon disease stability or progression.

For more information, contact Susan Hogan, the Myelodysplastic Syndromes Foundation, Inc.

Phone: 800-637-0839
Fax: 609-298-0590
E-mail: shogan@mds-foundation.org

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Alan D'Andrea indicated no conflicts of interest.
• Dr. Ulrich Germing: research support from Pharmion and Janssen- Cilag; advisory board for Pharmion, Celgene, and Genzyme.
• Dr. Denise Wells: research support from Hematologics, Inc.
• Dr. Allen Yang: research support from Pharmion and MethylGene; consultant for Pharmion and MGI Pharma.
• Dr. Jaroslaw Maciejewski: research support from the National Institutes of Health, Howard Hughes Foundation, and the Aplastic Anemia and MDS International Foundation; advisory board or speakers bureau for Genzyme, Celgene, Alexion, MGI Pharma, and Telik.
• Dr. Stephen Nimer: advisory board for MGI Pharma, Pharmion and Celgene.

Clinical Implications in the Diagnosis and Management of Invasive Fungal Infections: A Case-Based Approach
This program is sponsored by the Academy for Healthcare Education, Inc., and supported by Pfizer.

12:30 p.m. - 4:30 p.m. • Georgia World Congress Center – B216-B217

Speakers:

• John R. Wingard, MD, University of Florida Shands Cancer Center, Gainesville, FL
• Thomas F. Patterson, MD, University of Texas Health Science Center at San Antonio, San Antonio, TX
• Pranatharthi H. Chandrasekar, MD, Wayne State University School of Medicine, Detroit, MI

This symposium will focus on the diagnosis and management of invasive fungal infections. The didactic presentations and case study discussions will illustrate the clinical challenges of early diagnosis and difficult management decisions in the treatment of invasive fungal infections.

For more information, contact Christie Miller, the Academy for Healthcare Education, Inc.

Phone: 212-404-7730
Fax: 212-922-9164
E-mail: christie.miller@ahecme.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. John R. Wingard: consultant for Merck, Nectar Therapeutics, Pfizer, and Vical; speakers bureau for Merck and Pfizer.
• Dr. Thomas F. Patterson: research support from Enzon Pharmaceuticals, Merck, Nectar Therapeutics, Pfizer, and Schering-Plough; consultant for Astellas Pharma U.S., Inc., Basilea Pharmaceutica AG, Merck, Nectar Therapeutics, Pfizer, Schering- Plough, and Stiefel Laboratories; speakers bureau for Astellas Pharma U.S., Inc., Merck, Pfizer, and Schering-Plough.
• Dr. Pranatharthi Chandrasekar: research support from Pfizer Inc.; consultant for Enzon Pharmaceuticals, Inc. and Schering-Plough Corporation; speakers bureau for Pfizer Inc. and Schering-Plough Corporation.

Severing the Deadly Tie Between Thromboembolism and Cancer: A Case-Based Guide to Thromboprophylaxis in Malignancy
This program is sponsored by INNOVIA Education Institute, LLC, and supported by sanofi aventis U.S.

12:30 p.m. - 4:30 p.m. • Georgia World Congress Center – B405-B406

Speakers:

• Giancarlo Agnelli, MD, University of Perugia, Perugia, Italy
• Samuel Z. Goldhaber, MD, Brigham and Women’s Hospital, Boston, MA
• Michael B. Streiff, MD, The Johns Hopkins University School of Medicine, Baltimore, MD
• Ann K. Wittkowsky, PharmD, University of Washington Medical Center and School of Pharmacy, Seattle, WA
• Geno J. Merli, MD, Thomas Jefferson University School of Medicine, Philadelphia, PA
• Agnes Y. Lee, MD, Hamilton Health Sciences, Henderson General Hospital, Hamilton, Ontario, Canada

This symposium is aimed at educating oncologists, hematologists, critical-care specialists, and other health-care providers on venous thromboembolism (VTE) management and treatment for cancer patients.

For more information, contact Rachel Bealle, INNOVIA Education Institute, LLC.

Phone: 410-312-5189
Fax: 410-715-9195
E-mail: rbealle@innoviaeducation.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Giancarlo Agnelli indicated no conflicts of interest.
• Dr. Samuel Z. Goldhaber: consultant/research support from sanofi aventis U.S., Boehringer Ingelheim, Bristol-Myers Squibb, and Eisai; research support from GlaxoSmithKline and Mitsubishi Pharma Corporation.
• Dr. Michael B. Streiff: speakers bureau and consultant for sanofi aventis U.S., speakers buereau for GlaxoSmithKline, and consultant for Eisai.
• Dr. Ann K. Wittkowsky: consultant for sanofi aventis U.S..
• Dr. Geno J. Merli: research support from Bristol-Myers Squibb; research support from and speakers bureau for sanofi aventis U.S..
• Dr. Agnes Y. Lee: research support from Pfizer and Leo Pharma; consultant for sanofi aventis U.S., Scios, Bayer, Johnson and Johnson, Bristol-Myers Squibb, and Merck Frosst; advisory board member for Pfizer.

6:00 p.m. - 10:00 p.m.

The Management of Paroxysmal Nocturnal Hemoglobinuria: Recent Advances in Diagnosis and Treatment, and New Hope for Patients
This program is sponsored by the Postgraduate Institute of Medicine and supported by Alexion Pharmaceuticals, Inc.

6:00 p.m. - 10:00 p.m. • Georgia World Congress Center – B302-B305

Speakers:

• Neal S. Young, MD, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
• Gabrielle Meyers, MD, Oregon Health and Science University, Portland, OR
• Peter Hillmen, MB ChB, PhD, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
• Hubert Schrezenmeier, MD, Free University of Berlin, Berlin, Germany
• Anita Hill, MD, Bradford Teaching Hospitals NHS Foundation Trust and University of Leeds, Leeds, United Kingdom

Many physicians have never diagnosed or treated a patient with PNH. Indeed for them, PNH represents a section of a textbook and an interesting program at ASH. However, there have been many recent advances in both the diagnosis and management of this disease, and hematologists and oncologists should have a thorough knowledge of the ongoing clinical trials and an appreciation of the issues involved in order to make the best decisions for their patients.

For more information, contact Nelson Rosado, Fission Communications.

Phone: 646-742-3654
Fax: 646-742-3667
E-mail: nelson.rosado@fissioncommunications.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Neal S. Young indicated no conflicts of interest.
• Dr. Gabrielle Meyers: consultant for Alexion Pharmaceuticals, Inc.
• Dr. Peter Hillmen: research support from Alexion Pharmaceuticals, Inc.
• Dr. Hubert Schrezenmeier: lecture fees from Alexion
  Pharmaceuticals, Inc.
• Dr. Anita Hill: speaker and advisory board member for Alexion Pharmaceuticals, Inc.

Molecular Targets in T-Cell Disorders; Progress in Improving Therapeutic Outcomes
This program is sponsored by Physicians’ Education Resource and supported by Allos Therapeutics.

6:00 p.m. - 10:00 p.m. • Georgia World Congress Center – B312-B314

Speakers:

• Julie Vose, MD, University of Nebraska Medical Center, Omaha, NE
• Richard Fisher, MD, James P. Wilmot Cancer Center, Rochester, NY
• Owen O’Connor, MD, PhD, Columbia University, New York, NY
• Nam Dang, MD, Nevada Cancer Institute, Las Vegas, NV
• Madeleine Duvic, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX

New treatment options are being explored in clinical trials including monoclonal antibodies targeting T-cell surface antigens and small-molecule inhibitors of cell proliferation processes, such as histone acetylation/ deacetylation and regulation of protein turnover by the proteasome. The purpose of this symposium is to update physicians on newer treatment regimens currently undergoing clinical study in TCL.

For more information, contact Brad Randle, Physicians’ Education Resource.

Phone: 214-367-3496
Fax: 214-367-3303
E-mail: brad.randle@pergrouplp.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Julie Vose: research funding from Celgene, GlaxoSmithKline, Biogen Idec, Boehringer Ingelheim, Millennium Pharmaceuticals, and Genitope.
• Dr. Richard Fisher: consultant or advisory board for Allos Therapeutics, Genentech, and GlaxoSmithKline.
• Dr. Owen O’Connor: speakers bureau for Millennium Pharmaceuticals.
• Dr. Nam Dang: consultant or advisory board for Eisai, Ligand, Allos Therapeutics, Y’s Therapeutics, Innovatis, and Angelica Therapeutics.
• Dr. Madeline Duvic: member of the American Academy of Dermatology Board of Directors; research funding from Merck, Novartis, and Therakos; consultant for Merck, BioCryst, Eisai, and Gloucester Pharmaceuticals.

Thrombosis in Clinical Practice: Focus on VTE, AF, and Emerging Anticoagulants
This program is sponsored by the Academy for Healthcare Education, Inc. and supported by Boehringer Ingelheim Pharmaceuticals, Inc.

6:00 p.m. - 10:00 p.m. • Georgia World Congress Center – Georgia Ballroom

Speakers:

• Jeffrey Weitz, MD, FRCP(C), FACP, Hamilton Regional Cancer Centre, Hamilton, Canada
• Victor F. Tapson, MD, Duke University Medical Center, Durham, NC
• Jonathan L. Halperin, MD, The Mount Sinai Medical Center, New York, NY
• John A. Heit, MD, Mayo Clinic College of Medicine, Rochester, MN

This program will discuss the current issues associated with anticoagulation therapy. In patients with VTE, the use of anticoagulation for primary and secondary prevention will be reviewed along with discussion of the controversy of duration and intensity in secondary prevention. The use of longterm anticoagulation in patients with AF involves complex decisions, and recent guidelines have altered patient selection criteria. This program will review the indications and need for anticoagulation in patients with AF as well as complex decisions in selecting appropriate patients for anticoagulation.

For more information, contact Marie Boustani, Academy for Healthcare Education, Inc.

Phone: 212-404-7721
Fax: 212-338-9827
E-mail: marie.boustani@ahecme.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Jeffrey Weitz indicated no conflicts of interest.
• Dr. Victor F. Tapson: research support from and consultant for sanofi aventis U.S..
• Dr. Jonathan L. Halperin: consultant for Astellas Pharmaceuticals, Bayer HealthCare AG, Boehringer Ingelheim Pharmaceuticals, Daiichi-Sankyo Pharma Development, GlaxoSmithKline, Johnson and Johnson, and sanofi aventis U.S..
• Dr. John A. Heit indicated no conflicts of interest.

Evolution of Targeted and Multifunctional Agents for Leukemias and Lymphomas
This program is sponsored by Rush University Medical Center and supported by Cephalon, Inc.

6:00 p.m. - 10:00 p.m. • Georgia World Congress Center – C306-C308

Speakers:

• Stephanie Gregory, MD, Rush University Medical Center, Chicago, IL
• Donald Small, MD, PhD, The Johns Hopkins Hospital, Baltimore, MD
• Mathias Rummel, MD, PhD, Johann Wolfgang Goethe- Universitätsklinik, Frankfurt, Germany
• John Leonard, MD, Weill Medical College of Cornell University, New York, NY
• Martin S. Tallman, MD, Northwestern University, Chicago, IL
• Gail Roboz, MD, Weill Medical College of Cornell University, New York, NY

This educational symposium will provide the latest scientific data on emerging therapeutic modalities for both non-Hodgkin lymphoma and acute leukemia. With the recent introduction of targeted monoclonal antibodies, dramatic therapeutic developments have been made in treating hematologic tumors.

For more information, contact Robin Simak, Jonathan Wood and Associates.

Phone: 201-594-0400
Fax: 201-594-0409
E-mail: rsimak@jwoodassoc.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Stephanie Gregory: research support from Amgen, Astellas, Berlex, Biogen Idec, Boehringer Ingelheim, Celgene, Favrille, Genentech, Genitope, Genmab, Gloucester Pharmaceuticals, GlaxoSmithKline, Johnson and Johnson, Ligand, Merck, Millennium Pharmaceuticals, the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG), Novartis, Rigel, and Wyeth; consultant for Biogen Idec, Genentech, and GlaxoSmithKline; speakers bureau for Genentech, Biogen Idec, Celgene, and GlaxoSmithKline.
• Dr. Donald Small: research support from ImClone Systems, Inc., Ambit Biosciences, and Xanthus Pharmaceuticals.
• Dr. Mathias Rummel indicated no conflicts of interest.
• Dr. John Leonard: research support from Biogen Idec, Cephalon, Genentech, GlaxoSmithKline, Immunetics, Millennium Pharmaceuticals, and Seattle Genetics; consultant for Berlex, Biogen Idec, Bristol-Myers Squibb, Cougar Biotechnology, Genentech, GlaxoSmithKline, Millennium Pharmaceuticals, and Wyeth; speakers bureau for Biogen Idec, Genentech, GlaxoSmithKline, and Millennium Pharmaceuticals.
• Dr. Martin S. Tallman indicated no conflicts of interest.
• Dr. Gail Roboz: research support from and consultant for Cephalon.

Improving Outcomes in Acute Myeloid Leukemia
This program is sponsored by the Postgraduate Institute of Medicine and supported by EpiCept Corporation.

6:00 p.m. - 10:00 p.m. • Georgia World Congress Center – B211-B212

Speakers:

• Elihu Estey, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX
• Didier P. Blaise, Institut Paoli-Calmettes and Université de la Méditerranée, Marseille, France
• Mats Brune, MD, PhD, Sahlgrenska University Hospital, Goteborg, Sweden
• Bob Löwenberg, MD, PhD, Erasmus University Medical Center, Rotterdam, Netherlands
• Guido Marcucci, MD, The Ohio State University Medical Center, Columbus, OH
• Jeffrey Lancet, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
• Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, MD

The goal of the symposium and enduring material is to update hematologists and oncologists on ways to improve outcomes in AML.

For more information, contact Vaishali Soni, DesignWrite, LLC.

Phone: 609-436-2432
Fax: 609-497-2304
E-mail: vsoni@dwrite.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Elihu Estey indicated no conflicts of interest.
• Dr. Didier P. Blaise: advisory board member for EpiCept Corporation.
• Dr. Mats Brune: consultant for Maxim Pharmaceuticals and Epicept Corporation.
• Dr. Bob Löwenberg indicated no conflicts of interest.
• Dr. Guido Marcucci: advisory board member for MGI Pharma.
• Dr. Jeffrey Lancet: consultant for MGI Pharma; speaker for Pharmion.
• Dr. Mark Levis: consultant for Array BioPharma; laboratory funding from Kyowa Pharmaceutical, Inc.

Clinical Challenges in Non-Hodgkin Lymphoma – Biologic Strategies for 2008
This program is sponsored by Physicians’ Education Resource and supported by Genentech Biogen Idec.

6:00 p.m. - 10:00 p.m. • Georgia World Congress Center – Thomas Murphy Ballroom 1-2

Speakers:

• Sandra J. Horning, MD, Stanford Cancer Center, Stanford University, Stanford, CA
• Ian Flinn, MD, Sarah Cannon Research Institute, Nashville, TN
• Bertrand Coiffier, MD, Centre Hospitalier Lyon-Sud, Lyon, France
• Kristen Ganjoo, MD, Stanford University, Palo Alto, CA
• Anas Younes, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX
• Andres Forero-Torres, MD, University of Alabama at Birmingham, Birmingham, AL

The purpose of this symposium is to update physicians on the status of standard treatments for NHL and to discuss strategies for optimizing response through new agents.

For more information, contact Brad Randle, Physicians’ Education Resource.

Phone: 214-367-3496
Fax: 214-367-3303
E-mail: brad.randle@pergrouplp.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Sandra J. Horning: consultant or advisory board member for Genentech, Astellas Pharmaceuticals, Genmab, and Exelixis.
• Dr. Ian Flinn: research support from Genentech, Biogen Idec, and Cephalon; consultant or advisory board member for Cephalon and Protherics.
• Dr. Bertrand Coiffier: consultant or advisory board member for Roche, Genentech, Johnson and Johnson, and sanofi aventis U.S.; speakers bureau for Roche, Genentech, Millennium Pharmaceuticals, Johnson and Johnson, and sanofi aventis U.S..
• Dr. Kristen Ganjoo: research support from Genentech and Lilly Oncology; consultant or advisory board member for Genentech, GlaxoSmithKline; speakers bureau for Genentech.
• Dr. Anas Younes: speakers bureau for Genentech, Biogen Idec, and GlaxoSmithKline.
• Dr. Andres Forero-Torres: research support from Genentech, Biogen Idec, Cephalon, Seattle Genetics, Daiichi-Sankyo, and Eli Lilly.

EVENT CANCELED : DNA- and RNA-Based Therapeutics and Other Gene Silencing Strategies for Hematologic Malignancies: Applications for Apoptotic Targets
This program is sponsored by Medical Education Collaborative and supported by Genta, Inc.

6:00 p.m. - 10:00 p.m. • Georgia World Congress Center – Sidney Marcus Auditorium

Speakers:

• John C. Reed, MD, PhD, Burnham Institute for Medical Research, La Jolla, CA
• Anthony W. Tolcher, MD, FRCP, South Texas Oncology and Hematology, San Antonio, TX
• William G. Wierda, MD, PhD, The University of Texas M.D. Anderson Cancer Center, Houston, TX
• Tariq M. Rana, PhD, University of Massachusetts Medical School, Worcester, MA
• Carlo M. Croce, MD, College of Medicine and Public Health, The Ohio State University, Columbus, OH

In this symposium, the very latest developments in regulating cell function in hematologic malignancies will be presented.

Phone: 201-288-6262 x3233
Fax: 201-727-1735
E-mail: lauren.cirangle@neohealth.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. John C. Reed: consultant for Efficacy Capital; advisory board for Pharmion, Isis Pharmaceuticals, and Stratagene; speakers bureau for OSI Pharmaceuticals and Predictive Biosciences.
• Dr. Anthony W. Tolcher: consultant for Amgen, Anadys Pharmaceuticals, Ariad Pharmaceuticals, AstraZeneca, Astellas, Biogen Idec, Centocor, Compound Therapeutics, Cytokinetics, Eli Lilly, Exelixis, FibroGen, Five Prime Therapeutics, Genentech, Genetics Squared, Genta, ImmunoGen, Johnson and Johnson, MGI Pharma, National Cancer Institute Drug Development Group, Nereus Pharmaceuticals, Novacea, Paramount BioSciences, LLC, Park Place Pharmaceuticals, Pfizer, Sankyo, sanofi aventis U.S., Schering-Plough, and SuperGen.
• Dr. William G. Wierda: speakers bureau for Celgene; research support from Berlex Laboratories, sanofi aventis U.S., Memgen, Genitope, and Genmab.
• Dr. Tariq M. Rana: scientific advisor to CytRx and RXi Pharmaceuticals.
• Dr. Carlo M. Croce indicated no conflicts of interest.

Planning for Treatment With or Without Transplant: Balancing Efficacy, Toxicity, and Quality of Life for the Patient with Multiple Myeloma
This program is sponsored by the Institute for Continuing Healthcare Education and supported by the International Myeloma Foundation.

6:00 p.m. - 10:00 p.m. • Georgia World Congress Center – B216-B217

Speakers:

• Michel Attal, MD, PRD, Hopital Purpan, Toulouse, France
• Brian Durie, MD, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA
• Sundar Jagannath, MD, St. Vincent’s Comprehensive Cancer Center, New York, NY
• Antonio Palumbo, MD, University of Torino, Torino, Italy
• S. Vincent Rajkumar, MD, Mayo Clinic College of Medicine, Rochester, MN
• Jesus San-Miguel, MD, PhD, Hospital Universidad de Salamanca, Salamanca, Spain

After the symposium, participants should be able to identify the place-in-therapy for novel agents used in the management of patients with multiple myeloma and assess the most current clinical trial data on the efficacy and safety of multiple myeloma treatment regimens that include and that do not include transplantation. Participants will be able to design individualized treatment regimens that maximize efficacy, minimize toxicities, and improve patient quality of life.

For more information, contact Charisse Braithwaite, Institute for Continuing Healthcare Education.

Phone: 215-446-8088
Fax: 215-592-9085
E-mail: cbraithwaite@iche.edu

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Michel Attal: consultant and speakers bureau for Pharmion, Celgene, and Ortho Biotech.
• Dr. Brian Durie: consultant for Celgene, Millennium Pharmaceuticals, Ortho Biotech, and Kyphon, Inc.
• Dr. Sundar Jagannath: consultant for Millennium Pharmaceuticals; speakers bureau for Millennium Pharmaceuticals, Celgene, and Ortho Biotech; research support from Millennium Pharmaceuticals and AstraZeneca.
• Dr. Antonio Palumbo: consultant, speakers bureau, and research support from Pharmion, Celgene, and Ortho Biotech.
• Dr. S. Vincent Rajkumar: research support from Celgene.
• Dr. Jesus San-Miguel: consultant and speakers bureau for Celgene, Johnson and Johnson, and Pharmion.

Multiple Myeloma: Bringing Treatment Algorithms to Life
This program is sponsored by the Curatio CME Institute, LLC, and supported by Multiple Myeloma Research Foundation.

6:00 p.m. - 10:00 p.m. • Omni Hotel at CNN Center – Grand Ballroom D2-E

Speakers:

• Kenneth Anderson, MD, Dana-Farber Cancer Institute, Boston, MA
• Rafael Fonseca, MD, Mayo Clinic College of Medicine, Scottsdale, AZ
• Jean-Luc Harousseau, MD, University of Nantes, Nantes, France
• Robert Z. Orlowski, MD, PhD, University of North Carolina School of Medicine, Chapel Hill, NC
• Paul Richardson, MD, Harvard Medical School and Dana-Farber Cancer Institute, Boston, MA

This interactive event will consist of a panel-based discussion designed to present the current clinical challenges facing physicians who treat patients with multiple myeloma by reviewing and discussing the current clinical evidence to support or refute therapeutic options at each stage of the multiple myeloma treatment algorithm.

For more information, contact Kristen Petro, Curatio CME Institute, LLC.

Phone: 610-363-1619, ext. 115
Fax: 610-363-7410
E-mail: kristen.petro@curatiocme.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Kenneth C. Anderson: research support from and consultant for Celgene, Novartis, and Millennium Pharmaceuticals; speakers bureau for Celgene and Millennium Pharmaceuticals.
• Dr. Rafael Fonseca: research support from Pfizer; consultant for Millennium Pharmaceuticals, Novartis, and Genentech.
• Dr. Jean-Luc Harousseau: speaker for Ortho Biotech and Pharmion; consultant for Celgene, Millennium Pharmaceuticals, and Pharmion.
• Dr. Robert Z. Orlowski: consultant for Millennium Pharmaceuticals, Johnson and Johnson, Ortho Biotech, and Celgene.
• Dr. Paul Richardson: consultant for Celgene and Millennium Pharmaceuticals.

Clinical Challenges with Hereditary and Transfusion-Dependent Iron Overload
This program is sponsored by Physicians’ Education Resource and supported by Novartis Oncology.

6:00 p.m. - 10:00 p.m. • Omni Hotel at CNN Center – International Ballroom E-F

Speakers:

• Peter Greenberg, MD, Stanford School of Medicine, Palo Alto, CA
• Maria Domenica Cappellini, MD, University of Milan, Milan, Italy
• Pradyumna Phatak, MD, Lipson Cancer Center, Rochester, NY
• John Porter, MD, Royal Free and University College London, London, United Kingdom
• Roland Fischer, PhD, University Clinic Hamburg- Eppendorf, Hamburg, Germany

Iron-chelating agents are increasingly being used in the first- and second-line treatment of iron overload in patients with thalassemia, although their associated side effects have resulted in limited patient compliance. Novel iron chelating agents are being developed to improve patient compliance during chronic treatment. The purpose of this symposium is to educate physicians about the risks and treatment of iron overload.

For more information, contact Brad Randle, Physicians’ Education Resource.

Phone: 214-367-3496
Fax: 214-367-3303
E-mail: brad.randle@pergrouplp.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Peter Greenberg: consultant or advisory board for Amgen, Celgene, and Novartis; research support from Amgen, Novartis, Scios, and Celgene.
• Dr. Dr. Maria Domenica Cappellini: consultant or advisory board for Novartis; speakers bureau for Novartis.
• Dr. Pradyumna Phatak: consultant or advisory board for Novartis; speakers bureau for Novartis.
• Dr. John Porter: consultant or advisory board for Novartis and Genzyme; speakers bureau for Novartis.
• Dr. Roland Fischer indicated no conflicts of interest.

Unexpected Bleeding Diatheses: Diagnosis and Management
This program is sponsored by the FCG Institute for Continuing Education and supported by Novo Nordisk.

6:00 p.m. - 10:00 p.m. • Georgia World Congress Center – B405-B406

Speakers:

• David Green, MD, PhD, Northwestern Feinberg School of Medicine, Chicago, IL
• Amy D. Shapiro, MD, Indiana Hemophilia and Thrombosis Center, Indianapolis, IN
• Mark Reding, MD, University of Minnesota, Minneapolis, MN

After completing this continuing medical education activity, participants should be able to describe appropriate laboratory assays that may be used to differentiate acquired hemophilia from other bleeding disorders and evaluate the treatment options for bleeding related to acquired hemophilia. Participants will be able to evaluate available strategies for eradication of autoantibodies in acquired hemophilia.

For more information, contact Jennifer Kelly, Acumentis.

Phone: 215-412-5950
Fax: 215-412-0205
E-mail: jennifer.kelly@acumentis.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. David Green indicated no conflicts of interest.
• Dr. Amy D. Shapiro: consultant for Baxter BioScience, ProMetic, and Inspiration Biopharmaceuticals; speakers bureau for Baxter BioScience, Novo Nordisk, and Wyeth; research support from Baxter BioScience, Novo Nordisk, Bayer, Wyeth, Octagen Corporation, and ZLB Behring; advisory board for Bayer, Syntonix Pharmaceuticals, and the National Hemophilia Foundation.
• Dr. Mark Reding indicated no conflicts of interest.